This study is designed to compare the efficacy of intraperitoneal paclitaxel in combination with SOX, with SOX alone in the first-line treatment of gastric cancer with malignant ascites

Inclusion Criteria:

• had a histologically proven adenocarcinoma of the gastroesophageal junction, or stomach that was locally advanced (inoperable) or metastatic
• malignant ascites(over pelvic cavity in CT scan and confirmed by cytology)
• an Eastern Cooperative Oncology Group performance status of 0 to 2
• adequate renal, hepatic, and hematologic function

Exclusion Criteria:

• previous chemotherapy or radiotherapy (unless in the adjuvant setting)
• uncontrolled cardiac disease, or other clinically significant, uncontrolled
• coexisting illness or previous or concurrent cancer
• HER2 positive and willing to use trastuzumab